Skip to main navigation
Skip to search
Skip to main content
HSC Home
Home
Research units
Profiles
Publications
Sponsored Projects
Core Facilities
Search by expertise, name or affiliation
"One pill, once daily": What clinicians need to know about Atripla™
Overview
Fingerprint
Fingerprint
Dive into the research topics of '"One pill, once daily": What clinicians need to know about Atripla™'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Once-daily
100%
Antiretroviral
100%
Need to Know
100%
Atripla
100%
Pharmacokinetics
50%
Pharmaceutical Companies
50%
Dosing Device
50%
Drug Interactions
25%
Tolerability
25%
Adverse Effects
25%
Nave
25%
Clinical Application
25%
Fixed-dose Combination
25%
First-ever
25%
Clinical Implementation
25%
Antiretroviral Regimens
25%
Viral Suppression
25%
Renal Toxicity
25%
Bone Mineral Density
25%
Lipid Parameters
25%
Multiple Mechanisms of Action
25%
Adverse Drug
25%
Effect Interaction
25%
Marketed Products
25%
Hematologic Parameters
25%
Pharmacology, Toxicology and Pharmaceutical Science
Efavirenz Plus Emtricitabine Plus Tenofovir Disoproxil
100%
Pharmacokinetics
66%
Tolerability
33%
Adverse Event
33%
Drug Interaction
33%
Nephrotoxicity
33%